Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Phase 2

Active, not recruiting

Conditions: Atypical Teratoid Rhabdoid Tumor
Malignant Rhabdoid Tumor

Interventions: Drug: alisertib
Procedure: Surgical resection
Drug: methotrexate
Drug: cisplatin
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: topotecan
Drug: vincristine
Radiation: Radiation therapy

First Posted Date: 2014-04-15

Last Posted Date: 2024-10-31

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 125

Registration Number: NCT02114229

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States

and more 6 locations

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Ovarian Low Grade Serous Adenocarcinoma
Borderline Ovarian Serous Tumor
Micropapillary Serous Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Recurrent Primary Peritoneal Serous Adenocarcinoma
Ovarian Serous Adenocarcinoma

Interventions: Drug: Letrozole
Drug: Trametinib Dimethyl Sulfoxide
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tamoxifen Citrate
Drug: Topotecan

First Posted Date: 2014-04-02

Last Posted Date: 2025-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 260

Registration Number: NCT02101788

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 500 locations

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: ME-344
Drug: Topotecan

First Posted Date: 2014-03-31

Last Posted Date: 2017-10-02

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 46

Registration Number: NCT02100007

Locations: 🇬🇧
The Bays St Mary's Hospital, London, England, United Kingdom
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 7 locations

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: DFMO
Drug: Celecoxib
Drug: Cyclophosphamide
Drug: Topotecan

First Posted Date: 2014-01-09

Last Posted Date: 2024-02-09

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 30

Registration Number: NCT02030964

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇦🇺
Sydney Childrens Hospital KCC, Randwick, Australia
🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

and more 10 locations

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2

Completed

Conditions: Brain Neoplasms
Glioblastoma
Glioblastoma Multiforme
Gliosarcoma
Central Nervous System Neoplasms

Interventions: Drug: topotecan
Drug: pazopanib

First Posted Date: 2013-08-29

Last Posted Date: 2020-11-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01931098

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: cyclophosphamide
Drug: topotecan
Biological: hu14.18K322A
Procedure: peripheral blood stem cell harvest
Procedure: surgical resection
Drug: cisplatin
Drug: etoposide
Drug: doxorubicin
Drug: vincristine
Drug: busulfan
Drug: melphalan
Biological: peripheral blood stem cell transplantation
Biological: natural killer cell infusion
Radiation: radiation therapy
Biological: GM-CSF
Biological: G-CSF
Drug: mesna
Drug: levetiracetam
Biological: interleukin-2
Drug: Isotretinoin
Device: CliniMACS

First Posted Date: 2013-05-20

Last Posted Date: 2024-12-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 153

Registration Number: NCT01857934

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Phase 2

Active, not recruiting

Conditions: Retinoblastoma

Interventions: Drug: vincristine
Drug: topotecan
Drug: filgrastim
Drug: PEG-filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Other: focal therapy
Drug: etoposide
Drug: MESNA
Drug: doxorubicin
Procedure: enucleation
Radiation: external beam radiation or proton beam radiation

First Posted Date: 2013-02-05

Last Posted Date: 2024-04-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 174

Registration Number: NCT01783535

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Phase 2

Withdrawn

Conditions: Brain Metastases
Central Nervous System (CNS) Metastases

Interventions: Drug: Topotecan
Drug: Temozolomide

First Posted Date: 2012-11-29

Last Posted Date: 2017-09-19

Lead Sponsor: The Methodist Hospital Research Institute

Registration Number: NCT01736800

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Methodist Neurological Institute - Department of Neurosurgery, Houston, Texas, United States

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Veliparib
Drug: Topotecan

First Posted Date: 2012-09-24

Last Posted Date: 2015-06-10

Lead Sponsor: Vejle Hospital

Target Recruit Count: 22

Registration Number: NCT01690598

Locations: 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Topotecan
Drug: Sorafenib

First Posted Date: 2012-09-11

Last Posted Date: 2016-03-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 13

Registration Number: NCT01683149

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy